Evidence map›Paper›PMID 37235748›Full record

ArticleInflammatory bowel diseases2023

Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications.

Paul Hsu, Eunice J Choi, Shefali A Patel, William H Wong, Jocelyn G Olvera, Priscilla Yao, Yi Chia Liu, Matthew S Tsai, Wei Wang, Brigid S Boland and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory bowel diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Paul HsuDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Eunice J ChoiDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA.
Shefali A PatelDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
William H WongDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Jocelyn G OlveraDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Priscilla YaoDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Yi Chia LiuDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Matthew S TsaiDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Wei WangDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA.
Brigid S BolandDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
John T ChangDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID 0000-0003-0873-6218
University of California San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrea L Hevener · 2003 to 2026
$40.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Single-Cell Transcriptomic and Epigenetics CoreP01AI132122 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2018 to 2022
$9.8M
Training Grant in GastroenterologyT32DK007202 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 1985 to 2022
$7.7M
Resource-based Center for the study of the joint microenvironment in rheumatology (Overall Application)P30AR073761 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CORR, MARY P · 2018 to 2022
$3.9M
Rheumatic Diseases Research Training GrantT32AR064194 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARY S FIRESTEIN, Monica Guma · 2013 to 2026
$3.8M
Systems-level identification of key regulators deciding immune cell stateR01AI150282 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WANG, WEI · 2020 to 2024
$3.5M
Using single-cell RNA-seq to interrogate host immunity to pathogensR01AI123202 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHANG, JOHN T, YEO, EUGENE WEI-MING · 2016 to 2020
$3.1M
Role of proteasome activity in adaptive immunityR01AI129973 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHANG, JOHN T · 2018 to 2022
$2.2M
USING SINGLE-CELL RNA AND PROTEIN APPROACHES TO ELUCIDATE MOLECULAR DETERMINANTSAND PREDICTORS OF INFLAMMATORY BOWEL DISEASESK23DK123406 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOLAND, BRIGID S · 2020 to 2022
$720k
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
BLRD VA I01 BX005106CSRD VA I01 CX002396NCI NIH HHS P30 CA023100NIAID NIH HHS P01 AI132122NIAID NIH HHS R01 AI123202NIAID NIH HHS R01 AI129973NIAID NIH HHS R01 AI150282NIAMS NIH HHS P30 AR073761NIDDK NIH HHS K23 DK123406NIDDK NIH HHS P30 DK063491NIDDK NIH HHS P30 DK120515NIDDK NIH HHS T32 DK007202NIH HHS S10 OD026929
6 · The paper itself

Abstract

backgroundUlcerative colitis (UC) and Crohn's disease are 2 types of inflammatory bowel disease (IBD), a group of chronic digestive disorders caused by aberrant immune responses to intestinal microbes. Although changes in the composition of immune cell subsets in the context of IBD have been previously described, the interactions and communication among cells are less well understood. Moreover, the precise mechanisms of action underlying many biologic therapies, including the anti-α4β7 integrin antagonist vedolizumab, remain incompletely understood. Our study aimed to explore possible additional mechanisms through which vedolizumab acts.

methodsWe performed cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) on peripheral blood and colon immune cells derived from patients with ulcerative colitis treated with the anti-α4β7 integrin antagonist vedolizumab. We applied a previously published computational approach, NicheNet, to predict immune cell-cell interactions, revealing putative ligand-receptor pairs and key transcriptional changes downstream of these cell-cell communications (CCC).

resultsWe observed decreased proportions of T helper 17 (TH17) cells in UC patients who responded to vedolizumab and therefore focused the study on identifying cell-cell communications and signals of TH17 cells with other immune cells. For example, we observed that colon TH17 cells from vedolizumab nonresponders were predicted to have a greater degree of interactions with classical monocytes compared with responders, whereas colon TH17 cells from vedolizumab responders exhibited more interactions with myeloid dendritic cells compared with nonresponders.

conclusionsOverall, our results indicate that efforts to elucidate cell-cell communications among immune and nonimmune cell types may increase the mechanistic understanding of current and investigational therapies for IBD.

Indexed as

Colitis, UlcerativeInflammatory Bowel DiseasesAntibodies, Monoclonal, HumanizedCell CommunicationGastrointestinal AgentsHumansIntegrinsAntibodies, Monoclonal, HumanizedGastrointestinal AgentsIntegrinsvedolizumabcell-cell communicationssingle-cell RNA-sequencingT cellsulcerative colitisvedolizumab

Identifiers

PMID37235748
PMCPMC10547234
OpenAlexW4378363671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.